An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Mauna Kea Technologies to Present at 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Mauna Kea Technologies (Euronext: MKEA) announced its participation in the 32nd Annual Oppenheimer Healthcare investor conference, scheduled to be held virtually from March 15-17, 2022. Sacha Loiseau, Ph.D., Chairman and Founder, is set to present on March 17, 2022, at 8:40am Eastern Time. The company is renowned for its Cellvizio® platform, a real-time in vivo cellular imaging technology utilized across various medical specialties for disease monitoring and surgical guidance.
Positive
None.
Negative
None.
PARIS & BOSTON--(BUSINESS WIRE)--
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022.
Sacha Loiseau, Ph.D., Chairman and Founder, is scheduled to present on March 17, 2022, at 8:40am Eastern Time.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. All statements other than statements of historical fact included in this press release, including, without limitation, those regarding Mauna Kea Technologies’ financial condition, business, strategies, plans and objectives of management for future operations are forward-looking statements. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties, including the risks set forth in Chapter 3 of the 2020 Universal Registration Document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 17, 2021 under number D-21-0566 and the amendment to the 2020 Universal Registration Document filed with the AMF on September 17, 2021, which are both available on the Company's website (www.maunakeatech.com), and risks relating the economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. The distribution of this document may, in certain jurisdictions, be restricted by local regulations. Persons who come into possession of this document are required to observe all applicable local regulations relating to this document.
When is Mauna Kea Technologies presenting at the Oppenheimer Healthcare conference?
Mauna Kea Technologies is scheduled to present on March 17, 2022, at 8:40am Eastern Time.
What is the Euronext ticker for Mauna Kea Technologies?
The Euronext ticker for Mauna Kea Technologies is MKEA.
What is the Cellvizio platform by Mauna Kea Technologies?
The Cellvizio platform is a real-time in vivo cellular imaging technology that allows physicians to monitor disease progression and guide surgical interventions.
Where can I get more information about Mauna Kea Technologies?
More information about Mauna Kea Technologies can be found on their official website at www.maunakeatech.com.
What dates is the Oppenheimer Healthcare conference taking place?
The Oppenheimer Healthcare conference is taking place from March 15-17, 2022.
